Home
Drugs
Trastuzumab
Clinical Trials

Clinical Trials Related to Trastuzumab

Related studies linked through entity extraction aliases.

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Status: COMPLETED
Phase: PHASE2

An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

Status: COMPLETED
Phase: N/A

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Status: COMPLETED
Phase: PHASE2

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Status: WITHDRAWN
Phase: PHASE1/PHASE2

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Status: COMPLETED
Phase: PHASE2

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Status: COMPLETED
Phase: PHASE1

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

Status: UNKNOWN
Phase: PHASE2

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Status: WITHDRAWN
Phase: PHASE2

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Status: COMPLETED
Phase: PHASE1

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Status: TERMINATED
Phase: PHASE2

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Status: COMPLETED
Phase: PHASE2

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Status: TERMINATED
Phase: PHASE1/PHASE2

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Status: COMPLETED
Phase: PHASE1/PHASE2

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Status: COMPLETED
Phase: PHASE1

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Status: COMPLETED
Phase: PHASE1/PHASE2

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Status: COMPLETED
Phase: PHASE2

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Status: COMPLETED
Phase: PHASE3

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Status: COMPLETED
Phase: PHASE1

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Status: COMPLETED
Phase: PHASE2

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Status: COMPLETED
Phase: PHASE1/PHASE2